| Company Name: | Affymax, Inc. | | Ticker Symbol: | AFFY | | | WWW Address: | www.affymax.com |
| CEO: | Mr. John A. Orwin | | No. of Employees: | 130 |
| Common Issue Type: | CS | | Business Description: | Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.39 |  0.0 | 1.36 | 1.39 | 1.4 | 1.48 | 1.33 | 2021135 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 52.1 | 37.5 | 1.00 | -2.57 | 0.00 | 0.0 | 0.0 | 27.74 - 0.78 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.39 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 52.1 | mil |
| Latest Shares Outstanding | 37.5 | mil |
| Earnings pS (EPS) | -2.57 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 310,428 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 37.5 | mil |
| Float as % of Shares Outstanding | 99.9 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 244.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 141.70 | % |
| Gross Profit Margin | -34.1 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | -227.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 1029.0 | % |
| Current Ratio | 0.8 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | -0.37 | $ |
| Cash pS | 1.24 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.39 | $ |
| Cash Flow pS | -4.00 | $ |
| Free Cash Flow pS | -1.29 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -3.53 | |
| Price/Cash Flow | -0.3 | |
| Price/Free Cash Flow | -1.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 4.5 | 106 | 65,541 | 233,057 |
| 4 Weeks | 1.95 | 0.78 | 0.92 | 50.3 | 144 | 98,738 | 1,974,758 |
| 13 Weeks | 4.10 | 0.78 | 16.52 | -91.6 | 8 | 96,496 | 6,175,722 |
| 26 Weeks | 24.94 | 0.78 | 24.37 | -94.3 | 5 | 53,526 | 6,690,740 |
| 52 Weeks | 27.74 | 0.78 | 14.07 | -90.1 | 8 | 31,581 | 7,863,570 |
| YTD | 21.75 | 0.78 | - | -92.7 | 6 | 65,124 | 6,512,385 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.38 | 1.39 | 1.21 | 12.15 | 14.61 | 1.00 | 1.47 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -2.36 | 1.2 | -19.76 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -7.04 | NA | 77.84 |
| R&D | -13.13 | NA | -27.88 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -98.7 | -98.7 | 97.8 |
| Earnings % | -100.0 | -100.0 | 0.0 |
| EPS % | -100.0 | -100.0 | 0.0 |
| EPS $ | -1.58 | -1.58 | -0.73 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 2.91 |
| Current Ratio | 1.0 |
| Quick Ratio (Acid Test) | 1.0 |
| Liquidity Ratio (Cash) | 0.79 |
| Receivables Turnover | 7.5 |
| Average Collection Period | 48 |
| Working Capital/Equity | 41.5 |
| Working Capital pS | 0.09 |
| Cash-Flow pS | -2.44 |
| Free Cash-Flow pS | -1.10 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -2.56 |
| Financial Leverage Ratio (Assets/Equity) | 14.3 |
| Debt Ratio | 93.0 |
| Total Debt/Equity (Gearing Ratio) | 1.07 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 131.2 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 7.53 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.04 |
| Tobin's Q Ratio | 0.44 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -0.93 |
| Enterprise Value (EV)/Free Cash Flow | -1.66 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -3.53 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -0.3 |
| Price/Free Cash Flow Ratio - LTM | -1.1 |
| Price/Sales Ratio | 1.63 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 2.65 |
| Tangible Book Value pS - LTM | -0.39 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.22 |
| Cash pS - LTM | 1.24 |
| Cash Flow pS - LTM | -4.00 |
| Free Cash Flow pS - LTM | -1.29 |
| Earnings pS (EPS) | -2.57 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -43.70 |
| Free Cash Flow Margin 5YEAR AVG | -78.56 |
| Net Profit Margin | -99.0 |
| Net Profit Margin - 5YEAR AVRG. | -73.4 |
| Equity Productivity | 11.40 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 11.40 |
| Return on Capital Invested (ROCI) | -1128.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -142.6 |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | -79.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -44.4 |
| Gross Profit Margin | -34.1 |
| Gross Profit Margin - 5YEAR AVRG. | 91.3 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | -99.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -74.8 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 70 |
| Revenue per Employee | 310,428 |
| Net Income per Employee | -307,276 |
| Average Collection Period | 70 |
| Receivables Turnover | 7.5 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 16.36 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 27.47 |
| Fixed Assets Turnover | 6.01 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 1.38 |
| Revenue per $ Plant | 31.66 |
| Revenue per $ Common Equity | 11.40 |
| Revenue per $ Capital Invested | 11.40 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 95.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 50.1 |
| Research & Devlopment (R&D) as % of Revenue | 54.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 54.8 |
|
|  
|
| |
 |  |
